As reported by the figures gathered from The CDC and Prevention, adults with excess weight in the United States constitute almost 40 percent of the total population, which is alarming. For the first time in more than 10 years, it is remarkable that the obesity prevalence in American citizens had persisted at the same rate..
The CDC included this information in a report, which led to the study of the National Health and Nutrition Examination Survey (NHANES), an ongoing survey that actively conducts health and nutrition assessments across the USA.
The CDC Obesity Trends Measuring Methodology.
This is the obesity level that estimates placed in the year 2000 being 30 around there. CDC’s estimate of obesity prevalence for the year 2020 was 41.9 % prevalence. Now, according to forecasts from the 2021 – 2023 data, the prevalence of obesity was 40.3%.
While this small dip is not regarded as a cause for commotion, it, however, changes the upward trend in the level of opacity that had prevailed in many of the previous reports since 2011. The policy sets a target to reduce adult obesity to 36% or below by 2030, using slight adjustments and other strategies to maintain focus on the goal.
Who is Affected Most?
Severe obesity, having a BMI of 40 and above, still is on the increase. It increased from 7.7% among adults to 9.4%. They are at the highest health risks, such as heart problems and diabetes.
Obesity Across the U.S.
Recently, the CDC released a map that highlights the obesity rates in the Country by the states. A decade previously, seven states had obesity rates lower than 25.
Call for Action
Lastly, Dr. Karen Hacker, who heads the CDC’s National Center for Chronic Disease Prevention and Health Promotion, expresses frustration over the limited efforts to prevent and manage obesity. We need to elevate efforts to provide safe environments for exercise and make affordable, nutritious foods more accessible.
The Role of Cholesterol-lowering Medications, CDC Including Weight-Loss Drugs
The CDC prepared the release of the new data just before the Senate hearing with the head of Novo Nordisk, who manufactures drugs Ozempic and Wegovy, which are beneficial for diabetes, weight loss, and other related treatments. The discussion will pertain to the exorbitant cost of the medications.
There has been strong demand for these medications, as well as other such medicines produced by Eli Lilly, which have caused shortages for several years now. These experts also suggest that bringing down the price of making these weight loss drug complexes accessible can potentially help avert the loss of more than forty thousand American lives in a year.
